Zhang X, Han H, Zhao J, et al. A good response to furmonertinib second-line treatment of an advanced
lung adenocarcinoma patient with a rare EGFR exon 20 N771_P772insH mutation: A case report an d literature review. Front Pharmacol (IF: 5.988) . 2022 Aug 17;13:964606. doi: 10.3389/fphar.2022.964606. PMID: 36059942; PMCID: PMC9432720.